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Variation in contrast-associated acute
kidney injury prophylaxis for percutaneous
coronary intervention: insights from the
Veterans Affairs Clinical Assessment,
Reporting, and Tracking (CART) program
Joseph Walker Keach1,2*, Maggie A. Stanislawski3,4, Anna E. Barón3,4, Mary E. Plomondon3,4, Paula Langner3,
Amit Amin5, Heather M. Gilmartin3,4, Stephen Waldo2,3 and Thomas M. Maddox5,6

Abstract
Background: Contrast-Associated Acute Kidney Injury (CA-AKI) is a serious complication associated with
percutaneous coronary intervention (PCI). Patients with chronic kidney disease (CKD) have an elevated risk for
developing this complication. Although CA-AKI prophylactic measures are available, the supporting literature is
variable and inconsistent for periprocedural hydration and N-acetylcysteine (NAC), but is stronger for contrast
minimization.
Methods: We assessed the prevalence and variability of CA-AKI prophylaxis among CKD patients undergoing PCI
between October 2007 and September 2015 in any cardiac catheterization laboratory in the VA Healthcare System.
Prophylaxis included periprocedural hydration with normal saline or sodium bicarbonate, NAC, and contrast
minimization (contrast volume to glomerular filtration rate ratio ≤ 3). Multivariable hierarchical logistic regression
models quantified site-specific prophylaxis variability. As secondary analyses, we also assessed CA-AKI prophylaxis
measures in all PCI patients regardless of kidney function, periprocedural hydration in patients with comorbid CHF,
and temporal trends in CA-AKI prophylaxis.
(Continued on next page)

* Correspondence: walker.keach.md@gmail.com; joseph.keach@dhha.org
1
Department of Medicine, Denver Health Hospital Authority, 601 Broadway
MC4000, Denver, CO 80204, USA
2
Department of Medicine, University of Colorado, Aurora, CO, USA
Full list of author information is available at the end of the article
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.

Keach et al. BMC Nephrology

(2020) 21:150

Page 2 of 11

(Continued from previous page)

Results: From 2007 to 2015, 15,729 patients with CKD underwent PCI. 6928 (44.0%) received periprocedural
hydration (practice-level median rate 45.3%, interquartile range (IQR) 35.5–56.7), 5107 (32.5%) received NAC
(practice-level median rate 28.3%, IQR 22.8–36.9), and 4656 (36.0%) received contrast minimization (practice-level
median rate 34.5, IQR 22.6–53.9). After adjustment for patient characteristics, there was significant site variability
with a median odds ratio (MOR) of 1.80 (CI 1.56–2.08) for periprocedural hydration, 1.95 (CI 1.66–2.29) for
periprocedural hydration or NAC, and 2.68 (CI 2.23–3.15) for contrast minimization. These trends were similar
among all patients (with and without CKD) undergoing PCI. Among patients with comorbid CHF (n = 5893), 2629
(44.6%) received periprocedural hydration, and overall had less variability in hydration (MOR of 1.56 (CI 1.38–1.76))
compared to patients without comorbid CHF (1.89 (CI 1.65–2.18)). Temporal trend analysis showed a significant and
clinically relevant decrease in NAC use (64.1% of cases in 2008 (N = 1059), 6.2% of cases in 2015 (N = 128, p = <
0.0001)) and no significant change in contrast-minimization (p = 0.3907).
Conclusions: Among patients with CKD undergoing PCI, there was low utilization and significant site-level
variability for periprocedural hydration and NAC independent of patient-specific risk. This low utilization and high
variability, however, was also present for contrast minimization, a well-established measure. These findings suggest
that a standardized approach to CA-AKI prophylaxis, along with continued development of the evidence base, is
needed.
Keywords: Prevention, AKI, CA-AKI, PCI, CKD
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Background
Contrast-Associated Acute Kidney Injury (CA-AKI), defined as an absolute increase of serum creatinine ≥0.3
mg/dL or a relative increase ≥50% within 48–72 h of
contrast exposure, is a serious complication that may
occur after percutaneous coronary intervention (PCI)
[1]. CA-AKI is associated with increased morbidity, mortality, hospital length of stay, and healthcare costs [2–5].

Chronic kidney disease (CKD) is the strongest independent risk factor for developing CA-AKI [6]. Unfortunately,
effective therapies to reduce the clinical impact of CAAKI among CKD patients are largely absent. Thus, the
primary therapeutic objective is to reduce the likelihood
of developing CA-AKI among these patients. Numerous
prophylactic interventions have been studied, including
periprocedural intravenous hydration with normal saline
(NS) or sodium bicarbonate, periprocedural administration of N-Acetylcysteine (NAC), and the minimization
of contrast volume [7–11]. The strength of evidence
supporting NAC and specific periprocedural hydration
protocols is weak, while minimizing procedural contrast
volume is much stronger [7–11]. Major society guidelines on CA-AKI prophylaxis in CKD patients are
currently lacking or contradictory [12, 13]. We hypothesized that such variability in the literature and guidelines
would result in significant site-level practice variation independent of patient-specific factors. We also hypothesized there would be less variability in well-established
interventions, such as contrast minimization. With this
in mind, we sought to assess the prevalence and variation of CA-AKI prophylactic measures utilized in CKD
patients undergoing PCI throughout the largest integrated healthcare system in the United States, the Veterans Affairs (VA) Healthcare System, with hopes of
identifying opportunities to improve the use of prophylactic measures and reduce the incidence of CA-AKI.

Methods
The VA CART program is a national clinical quality initiative for all VA cardiac catheterization laboratories.
The program seeks to enhance the quality and safety of
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invasive cardiovascular procedures throughout the VA
[14]. The CART program collects standardized data on
all coronary angiograms and percutaneous coronary
interventions. Software is embedded in the VA electronic health record (EHR) and allows providers to enter
patient and procedural information as part of routine
clinical workflow. The CART software was designed
using standardized definitions which conform to the
definitions and standards of the American College of
Cardiology’s National Cardiovascular Data Registry
(ACC-NCDR) [15]. Quality checks of the data are periodically conducted for completeness and accuracy [16].
CART data are combined with other VA data sources to
create a longitudinal data repository that supports quality assessment and improvement across the integrated
healthcare system.
We evaluated the use of periprocedural hydration with
normal saline or sodium bicarbonate, periprocedural
NAC, and the volume of contrast used during PCI relative to the patient’s GFR among patients with CKD
undergoing PCI between October 1st 2007 and September 30th 2015 at any VA cardiac catheterization laboratory. Prior studies have indicated that ratios of contrast
volume relative to GFR < 3 are associated with lower
CA-AKI risk [10]. CKD was defined as a glomerular filtration rate (GFR) of 15-59 mL/min. The use of periprocedural hydration was determined from in-lab records
and/or inpatient medications within 48 h of the procedure and included the administration of normal saline
(NS) or intravenous sodium bicarbonate. Doses of periprocedural hydration < 100 mL were excluded to avoid
mistaking saline flushes and other small saline applications for CA-AKI pre-hydration. The median volume of
preprocedural hydration administered using this approach was 1000 ml (IQR: 500–1000 ml). The use of
NAC was determined from in-lab records and/or outpatient prescription data, including prescriptions for < 3
days of NAC given within 30 days of the procedure. The
PCI providers recorded contrast volume administration
in the EHR. GFR levels were calculated using the Modification of Diet in Renal Disease (MDRD) equation,
using the most recent serum creatinine value recorded
within 30 days of the PCI [17]. Patients were excluded
for currently receiving hemodialysis, missing preprocedural GFR assessment, missing longitudinal followup data, undergoing repeat PCI, or receiving PCI at a
facility that performed < 50 PCIs over the time frame of
the study.
We assessed patient demographic and clinical risk factors, including age, race (white, black, other), sex, presence of congestive heart failure (CHF), GFR, and history
of diabetes, from the EHR using standard definitions
[15]. Lesion risk (defined as high or non-high) and number of stents were determined by data entered into the
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CART application by physicians. Annual PCI volume
was assessed using CART data.
We compared demographic, clinical, and CA-AKI
prophylaxis characteristics of CKD patients undergoing
PCI by catheterization laboratory rates of periprocedural
hydration or NAC use, stratified into quartiles. We used
chi-squared tests for categorical variables and Mann–
Whitney Wilcoxon tests for continuous variables. We
then calculated unadjusted rates of 1) Periprocedural hydration, 2) NAC use, 3) periprocedural hydration or
NAC use, and 4) contrast: GFR ≤ 3. Median site-level
rates with interquartile ranges were calculated.
Next, to evaluate the variation in use of site-level
CA-AKI prophylaxis measures independent of patient
CA-AKI risk, we calculated adjusted rates of 1) periprocedural hydration, 2) periprocedural hydration or
NAC, and 3) contrast: GFR ≤ 3. We did not model the
outcome of NAC due to instability in statistical models
caused by the wide variation in NAC use across sites
with very small numbers at many sites. For the analysis
of each prophylaxis measure, catheterization laboratories were excluded if the prophylactic measure was used
infrequently (< 20 times over the study period) to avoid
unstable estimates. For the contrast: GFR ratio analyses, PCI patients who had missing contrast volume
information were excluded.
We used hierarchical regression models with VA
catheterization laboratory sites as a random intercept to
adjust for differences in lab case mix and to account for
the clustering of patients by lab, similar to the methodology used in calculating hospital-level readmission data
by the Centers for Medicare and Medicaid [18]. Based
on prior literature and a priori clinical knowledge, we
adjusted for the following patient level characteristics associated with CA-AKI: age, race, sex, CHF, GFR, diabetes, lesion risk (at least 1 high risk vs all non-high
risk), number of stents, and year of PCI, as well as sitelevel annual PCI volume. Lesion risk and number of
stents were included as surrogates for PCI complexity.
For binary outcomes, we used logistic regression models
to calculate the predicted and expected probability of
each prevention measure at each lab and then multiplied
this ratio by the mean rate across sites to get the standardized site-level rate [19]. We estimated the 95%
confidence interval using bootstrap sampling. We considered the lab proportion as significantly different from
average when the 95% confidence interval did not include the system-wide mean.
We used the median odds ratio (MOR) to describe the
level of variation between sites, independent of patient
factors. The MOR can be interpreted as the odds that 2
patients with identical patient-level covariates from 2
randomly chosen sites will receive similar treatments, or
in our case, prophylaxis. An MOR of 1.0 indicates that
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no variation exists between sites, and identical patients
would receive identical treatment at different sites. The
MOR is always ≥1. For example, an MOR of 1.5
indicates a 50% likelihood that a similar patient would
receive different prophylactic measures at 2 different
sites. It provides an estimate of the effect of the
catheterization laboratory on the outcome, much as the
odds ratio (OR) estimates the effect of patient factors on
the outcome. Based on previous literature, an MOR >
1.2 indicates moderate site-level variation [20].
We also performed several secondary analyses. First, we
expanded the cohort to all patients undergoing PCI, regardless of kidney function. Methods for this analysis of all patients were identical to those used for the primary analysis.
Second, to evaluate the potential effect of comorbid
CHF on the volume of IV fluid administered for prophylaxis, we stratified the cohort by presence of CHF. We
then performed hierarchical regression models of periprocedural hydration, identical to those used for the primary analysis, to estimate use, and variation in use,
within each stratum.

Fig. 1 Primary cohort flow diagram
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Finally, to explore the temporal changes in prophylaxis, a linear trend test was applied to unadjusted rates
of use of each measure by fiscal year.
All statistical analyses were performed by the CART
Program Analytic Center using SAS version 9.4 (SAS Institute Inc., Cary, North Carolina) and R 3.4.1 (R Core
Team (2019). The Colorado Multiple Institutional Review Board approved the study.

Results
Between 2007 and 2015, 87,056 PCIs were performed
across the VA integrated healthcare system. As shown in
Fig. 1, PCIs were excluded if patients were currently receiving hemodialysis (N = 2727), missing pre-procedural
GFR assessment (N = 4567), without longitudinal followup data (N = 2), undergoing repeat PCI (N = 15,588), sites
with < 50 PCIs over the time frame of the study (N = 37),
and or had normal kidney function (N = 48,406). Thus,
the cohort for our primary analysis included 15,729 patients with CKD undergoing PCI at 64 unique sites.
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Table 1 shows the characteristics of the primary CKD
cohort, both overall and arranged by quartile of increasing unadjusted rates of periprocedural hydration or
NAC use. Among these 15,729 patients, 6928 (44.0%) received periprocedural hydration (practice-level median
rate 45.3%, interquartile range (IQR) 35.5–56.7), 5107
(32.5%) received NAC (practice-level median rate 28.3%,
IQR 22.8–36.9), and 9436 (60.0%) received periprocedural hydration or NAC (practice-level median rate 62.8,
IQR 50.7–72.4). The median contrast: GFR ratio was 3.6,
(IQR 2.5–5.1) and 4656 (36.0%) patients received contrast minimization (contrast: GFR ratio ≤ 3, practice-level
median rate 34.5, IQR 22.6–53.9). After adjusting for
patient-specific risk factors, the MOR for only periprocedural hydration was 1.80 (CI 1.59–2.08), for periprocedural hydration or NAC was 1.95 (confidence interval
[CI] 1.66–2.29), and contrast: GFR ratio ≤ 3 was 2.68 (CI
2.23–3.15) (Table 2; Figs. 2 and 3). The intracluster correlation coefficient for periprocedural hydration was
0.07, for hydration or NAC, 0.13, and for contrast
minimization, 0.18.
For our secondary analysis of all PCI patients, we
included all patients undergoing PCI during the study
period regardless of kidney function. Among this cohort of 64,135 PCI patients, 22,888 (35.7%) received
periprocedural hydration, 8919 (13.9%) received NAC,
and 27,595 (43%) received periprocedural hydration or
NAC. The median contrast volume to GFR ratio was
2.5 (IQR 1.6–3.7) and 32,503 (62.3%) patients had a
contrast: GFR ratio < = 3. After adjustment, the MOR
for periprocedural hydration was 1.96 (CI 1.71–2.24),
and for periprocedural hydration or NAC use was
2.15 (CI 1.82–2.53). The MOR for a contrast: GFR ratio ≤ 3 was 2.75 (CI 2.26–3.28) (Table 2; Supplemental
Figs. 1 and 2).
For our secondary analysis of comorbid CHF and periprocedural hydration, 5893 (37.5%) patients from our
primary cohort had CHF (9836 had CKD but not CHF).
2629 (44.61%) patients with CHF received periprocedural hydration, while 4299 (43.71%) of those without
CHF received hydration. After adjusting for patientspecific risk factors, the MOR for any periprocedural hydration among patients with CHF was 1.56 (1.38–1.76).
For those without CHF, the MOR was 1.89 (1.65–2.18)
(Supplemental Fig. 3).
Finally, for our secondary analysis of temporal
prophylaxis trends, there was a significant and clinically relevant decrease in NAC use over the study
period, with NAC being used in 64.1% of cases in
2008 (N = 12,059), and only 6.2% of cases in 2015
(N = 128, p = < 0.0001) (Supplemental Tables 1a, b, c).
Contrast minimization appeared to stay constant with
no significant trend change over the study period
(p = 0.3907).
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Discussion
Our analysis of CA-AKI prophylaxis among patients
with CKD undergoing PCI in the national VA healthcare
system demonstrated low utilization of commonly
employed prophylactic measures, as well as a high level
of variability in practice patterns, independent of
patient-specific risk. This low utilization and high variability were present for well-established, as well as less
established, prophylactic measures and similar trends
were noted in PCI patients with and without CKD. We
expected there would be less variability in CA-AKI
prophylaxis in the highest risk population, patients with
CKD, compared to the general PCI population. We
found, however, that high levels of variability persisted
among CKD patients, with contrast minimization even
more variable in this population.
Among patients with CKD, periprocedural hydration
and NAC, both poorly-established interventions, were
administered in a little over half of procedures, and had
an MOR of 1.80, indicating that identical patients would
have roughly 2-fold greater odds of receiving hydration
or NAC by being treated in one facility compared to another. However, the well-established measure of contrast
minimization had even higher variability by site (MOR
2.68). This demonstrates that identical patients with
CKD have almost 3-fold greater odds of receiving high
volumes of contrast in 1 cardiac catheterization laboratory compared to another.
Among patients with comorbid CHF, we found that
patients with CKD and comorbid CHF received periprocedural hydration at a similar frequency (44.61% vs
43.71%). Furthermore, after risk adjustment, there was
less variability in periprocedural hydration of patients
with CHF than those without (MOR 1.56 vs 1.89, respectively). This is likely related to provider preference
and avoidance of potential volume overload in patients
at high risk for this complication (patients with impaired
cardiac and renal function).
Our study evaluated 8 years of CA-AKI prophylaxis
practice patterns. During this time significant research
was published and subsequent guidelines updated. We
observed a statistically significant and clinically relevant
decrease in the use of NAC prophylaxis over the time
course of our study, falling from 64.1% of cases in 2008
to only 6.2% in 2015. This is likely related to highquality research demonstrating the lack of benefit of
NAC for CA-AKI prophylaxis, and the updated 2011
ACC/AHA/SCAI guidelines recommended against the
use of NAC [12]. Of note, the well-established prophylactic measure of contrast-minimization remained relatively low and constant throughout our study period.
Contrast-minimization was on average utilized only
36.0% of the time and ranged from 33.6 to 38.9% with
no significant increase in utilization over time.
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Table 1 Demographic and clinical characteristics of patients with CKD receiving PCI arranged by site quartile of unadjusted rates of
periprocedural hydration or NAC use
Variable

Total
(N = 15,729)

QUARTILE 1
(N = 3507)

QUARTILE 2
(N = 4108)

QUARTILE 3
(N = 4511)

QUARTILE 4
(N = 3603)

p-value

Age (Median (IQR))

68.6 (63.6–76.9)

68.8 (63.5–76.8)

67.7 (63.1–75.6)

68.6 (63.4–76.9)

70.0 (64.3–78.7)

<.0001

Male

15,429 (98.1%)

3439 (98.1%)

4022 (97.9%)

4438 (98.4%)

3530 (98.0%)

0.38

<.0001

Demographics

Race
White

13,613 (86.5%)

2997 (85.5%)

3525 (85.8%)

3919 (86.9%)

3172 (88.0%)

Black

1799 (11.4%)

421 (12.0%)

525 (12.8%)

515 (11.4%)

338 (9.4%)

Other

317 (2.0%)

89 (2.5%)

58 (1.4%)

77 (1.7%)

93 (2.6%)

Cormorbidities
Hypertension

14,973 (95.2%)

3332 (95.0%)

3953 (96.2%)

4242 (94.0%)

3446 (95.6%)

<.0001

Hyperlipidemia

14,413 (91.6%)

3146 (89.7%)

3855 (93.8%)

4077 (90.4%)

3335 (92.6%)

<.0001

Diabetes

9127 (58.0%)

2060 (58.7%)

2407 (58.6%)

2552 (56.6%)

2108 (58.5%)

0.14

Tobacco Use

9124 (58.0%)

1916 (54.6%)

2599 (63.3%)

2339 (51.9%)

2270 (63.0%)

<.0001

Prior MI

6728 (42.8%)

1503 (42.9%)

1804 (43.9%)

1860 (41.2%)

1561 (43.3%)

0.071

Prior PCI

6018 (38.3%)

1328 (37.9%)

1602 (39.0%)

1743 (38.6%)

1345 (37.3%)

0.43

Congestive Heart Failure

5893 (37.5%)

1330 (37.9%)

1503 (36.6%)

1711 (37.9%)

1349 (37.4%)

0.56

Cerebrovascular Disease

3803 (24.2%)

881 (25.1%)

982 (23.9%)

1034 (22.9%)

906 (25.1%)

0.055

Peripheral Arterial Disease

4451 (28.3%)

970 (27.7%)

1152 (28.0%)

1220 (27.0%)

1109 (30.8%)

0.0016

Hx of CKD Dx

8707 (55.4%)

1876 (53.5%)

2319 (56.5%)

2308 (51.2%)

2204 (61.2%)

<.0001

Chronic Obstructive Pulmonary
Disease

4136 (26.3%)

930 (26.5%)

1035 (25.2%)

1229 (27.2%)

942 (26.1%)

0.19

BMI (Median (IQR))

29.9 (26.4–34.0)

30.0 (26.6–34.1)

30.1 (26.6–34.2)

29.7 (26.1–33.7)

29.9 (26.4–34.1)

0.0048

Chronic Depression

4407 (28.0%)

1004 (28.6%)

1263 (30.7%)

1213 (26.9%)

927 (25.7%)

<.0001

Sleep Apnea

3596 (22.9%)

765 (21.8%)

1008 (24.5%)

993 (22.0%)

830 (23.0%)

0.014

Baseline Cholesterol (Median (IQR))

157.7 (135.3–
185.0)

161.5 (138.0–
189.0)

160.1 (137.2–
188.0)

155.2 (133.0–
183.0)

154.0 (133.0–
181.0)

<.0001

Baseline LDL (Median (IQR))

85.8 (67.7–108.4)

86.3 (68.3–110.0)

87.1 (68.0–109.2)

86.0 (68.0–108.3)

83.3 (66.0–106.0)

<.0001

Baseline HDL (Median (IQR))

36.7 (31.0–43.5)

36.6 (31.0–43.6)

36.5 (31.0–43.0)

36.3 (31.0–43.0)

37.1 (31.7–44.3)

0.0006

3a

11,029 (70.1%)

2404 (68.5%)

2958 (72.0%)

3140 (69.6%)

2527 (70.1%)

0.02

3b

3927 (25.0%)

915 (26.1%)

981 (23.9%)

1135 (25.2%)

896 (24.9%)

4

773 (4.9%)

188 (5.4%)

169 (4.1%)

236 (5.2%)

180 (5.0%)

Baseline GFR (Median (IQR))

50.4 (43.0–55.7)

50.0 (42.4–55.1)

50.9 (43.8–56.0)

50.6 (43.0–56.0)

50.2 (42.9–55.3)

0.0012

Elective

9617 (61.1%)

2275 (64.9%)

2744 (66.8%)

2545 (56.4%)

2053 (57.0%)

<.0001

Emergent/Urgent

6034 (38.4%)

1220 (34.8%)

1329 (32.4%)

1947 (43.2%)

1538 (42.7%)

78 (0.50%)

12 (0.3%)

35 (0.9%)

19 (0.4%)

12 (0.3%)

STEMI

1094 (7.0%)

263 (7.5%)

252 (6.1%)

336 (7.4%)

243 (6.7%)

NSTEMI

3515 (22.3%)

756 (21.6%)

789 (19.2%)

1074 (23.8%)

896 (24.9%)

Unstable Angina

3516 (22.4%)

682 (19.4%)

1154 (28.1%)

918 (20.4%)

762 (21.1%)

ACS

182 (1.2%)

39 (1.1%)

44 (1.1%)

74 (1.6%)

25 (0.7%)

Stable Angina

4693 (29.8%)

1218 (34.7%)

1119 (27.2%)

1285 (28.5%)

1071 (29.7%)

CKD class

Procedural Details
PCI Status

Missing
PCI Indication

<.00
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Table 1 Demographic and clinical characteristics of patients with CKD receiving PCI arranged by site quartile of unadjusted rates of
periprocedural hydration or NAC use (Continued)
Variable

Total
(N = 15,729)

QUARTILE 1
(N = 3507)

QUARTILE 2
(N = 4108)

QUARTILE 3
(N = 4511)

QUARTILE 4
(N = 3603)

Other/Missing

2729 (17.4%)

549 (15.7%)

750 (18.3%)

824 (18.3%)

606 (16.8%)

At least 1 lesion of high risk

6586 (41.9%)

1578 (45.0%)

1535 (37.4%)

2056 (45.6%)

1417 (39.3%)

<.0001

Number of stents (Median (IQR))

1.0 (1.0–1.0)

1.0 (1.0–1.0)

1.0 (1.0–1.0)

1.0 (1.0–1.0)

1.0 (1.0–1.0)

0.64

950 (26.4%)

<.0001

p-value

CA-AKI Prevention Measures
Mutually Exclusive Categories of Preventions
None

6293 (40.0%)

2028 (57.8%)

1778 (43.3%)

1537 (34.1%)

Only NS

4329 (27.5%)

533 (15.2%)

1004 (24.4%)

1464 (32.5%)

1328 (36.9%)

Only NAC

2508 (15.9%)

691 (19.7%)

604 (14.7%)

572 (12.7%)

641 (17.8%)

NAC and Saline

2599 (16.5%)

255 (7.3%)

722 (17.6%)

938 (20.8%)

684 (19.0%)

Any NAC

5107 (32.5%)

946 (27.0%)

1326 (32.3%)

1510 (33.5%)

1325 (36.8%)

<.0001

Any Hydration

6928 (44.0%)

788 (22.5%)

1726 (42.0%)

2402 (53.2%)

2012 (55.8%)

<.0001

Hydration or NAC

9436 (60.0%)

1479 (42.2%)

2330 (56.7%)

2974 (65.9%)

2653 (73.6%)

<.0001

Contrast use

(N = 12,938)

(N = 2988)

(N = 3096)

(N = 3720)

(N = 3134)

Contrast (Median (IQR))

175.0 (120.0–
246.0)

165.0 (100.0–
230.0)

175.0 (120.0–
240.0)

190.0 (132.0–
260.0)

165.0 (105.0–
235.0)

<.0001

Contrast:GFR (Median (IQR))

3.6 (2.5–5.1)

3.4 (2.2–5.0)

3.6 (2.5–5.1)

4.0 (2.8–5.4)

3.5 (2.3–4.9)

<.0001

Contrast:GFR ≤ 3

4656 (36.0%)

1206 (40.4%)

1136 (36.7%)

1081 (29.1%)

1233 (39.3%)

<.0001

To our knowledge, only a small number of studies
have investigated the prevalence of CA-AKI prophylactic
measure utilization, none of which analyzed contrast
minimization strategies, or PCI and CKD specifically
[21–24]. A 2008 single-center study by Weisbord et al.
prospectively identified 660 patients with CKD undergoing intravenous and intra-arterial contrasted studies and
showed that periprocedural fluids were administered in
40% of patients and NAC was administered in 39.2%
[23]. A 2014 study by Lee et al. retrospectively analyzed
the incidence of CA-AKI and prevalence of prophylactic
measure utilization with intravenous contrasted computed tomography (CT) scans. They identified 101,487
patients with 140,838 contrasted CT scans and found
the incidence of prophylactic medication utilization to
be 28.6%, mostly driven by NS use (26%) [24].
Table 2 Risk-Adjusted Median Odds Ratio for CA-AKI
prophylaxis measures in PCI patients with CKD and all PCI
patients (CKD or normal kidney function)
CKD Patients

All Patients

MOR

95% CI

MOR

95% CI

Hydration

1.80

1.59–2.08

1.96

1.71–2.24

Hydration or NAC

1.95

1.66–2.29

2.15

1.82–2.53

Contrast:GFR Ratio ≤ 3

2.68

2.23–3.15

2.75

2.26–3.28

Estimates risk-adjusted for the following: CHF, age, sex, race (white, black,
other), GFR, diabetes, lesion risk (at least 1 high vs all non-high), # of stents,
year of PCI, and annual hospital PCI volume

Compared to these, our study specifically analyzed the
prevalence of CA-AKI prophylaxis surrounding PCI in
patients with and without CKD, including contrast
minimization. Our finding of periprocedural hydration
or NAC administration in 43% of cases (patients with
and without CKD) is within range of prior literature. In
addition, we add to this literature with our demonstration of a high level of patient-adjusted variability in CAAKI prophylaxis among high-risk patients, including
contrast minimization, and accounting for patient-level
risk factors.
The significant variation in CA-AKI prophylaxis
likely reflects the ambiguity of the underlying data,
particularly in light of recent randomized clinical trials. A study by Nijssen et al. demonstrated no benefit
when comparing periprocedural hydration with NS to
no intravenous hydration at all [25]. The PRESERVE
trial randomly assigned 5177 patients to receive periprocedural hydration with intravenous sodium bicarbonate or NS, as well as either NAC or placebo, in a
2-by-2 factorial design. The study demonstrated no
benefit of sodium bicarbonate compared to NS, as
well as no benefit of NAC when compared to placebo
[26].
Conflicting major society guidelines likely compound the effect of the contradictory literature. The
2011 ACCF/AHA/SCAI guidelines for PCI recommend periprocedural intravenous hydration without a
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Fig. 2 Plot of risk-adjusted, site-level rates of hydration and NAC prophylaxis in PCI patients with CKD. The estimates are shown with 95%
confidence intervals (CIs) for those that differ significantly from the system-wide average. Estimates are risk-adjusted for the following: CHF, age,
sex, race (white, black, other), GFR, diabetes, lesion risk (at least 1 high vs all non-high), number of stents, year of PCI, and annual hospital
PCI volume

specific protocol for volume or timing of hydration
and recommend against NAC [12]. The 2012 KDIGO
guidelines recommend periprocedural intravenous hydration without specific protocols for volume or timing of hydration, however they do recommend the
use of NAC [13]. Accordingly, this inconsistency in
the hydration and NAC guidelines makes our findings
of high variability in their utilization somewhat
expected.
In contrast to these inconsistencies, there is broad
consensus and guideline support for minimizing contrast
during PCI, and numerous studies have demonstrated a
contrast: GFR volume < 3 is associated with lower rates
of CA-AKI [10]. This makes our findings of high variability in contrast minimization, both in our overall
population and among those with CKD, very surprising.
Our study had several limitations, the first being that
our outcomes were determined from analyzing the

electronic health record, and some data may have been
incompletely or inaccurately recorded, with accuracy
varying by site. This could have resulted in inaccurate
measurement of prophylactic measures. Second, the results may be subject to confounding variables not
accounted for by our statistical models. We adjusted for
numerous variables associated with CA-AKI, however,
there could be unaccounted for confounders that influenced our results. Third, we used an arbitrary volume of
> 100 mL periprocedural hydration as a cutoff for receiving prophylactic hydration. However, the most commonly used NS hydration protocols (3–4 mL/kg per
hour 4 h before and 4 h after contrast administration, or
1 mL/kg per hour 12 h before and 12 h after) would administer 1.5–2.0 l of NS for a typical 70 kg patient; thus
a cutoff of 100 mL of NS likely over estimates the rate of
prophylactic NS administration [25]. Fourth, there are
numerous other CA-AKI prophylactic strategies
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Fig. 3 Plot of risk-adjusted site-level PCIs with contrast to GFR ratios ≤3 among PCI patients with CKD. The estimates are shown with 95%
confidence intervals (CIs) for those that differ significantly from the system-wide average. Estimates are risk-adjusted for the following: CHF, age,
sex, race (white, black, other), GFR, diabetes, lesion risk (at least 1 high vs all non-high), number of stents, year of PCI, and annual hospital
PCI volume

available, including statin therapy and ascorbic acid,
which were not evaluated in this study. However, as
periprocedural
hydration,
NAC,
and
contrast
minimization have the strongest body of evidence supporting their use, we believe they are adequate surrogates. Fifth, there is ongoing debate in the literature on
the prevalence and nature of CA-AKI, with some evidence suggesting the prevalence is lower than originally
thought [27]. This underlying confusion, however, likely
leads to some of the variation we identified, and until
this condition is better understood practice variation will
continue. Sixth, we did not capture whether certain
nephrotoxic home medications were held or continued
(diuretics, NSAIDs, ACE/ARB/RAAS inhibitors, etc.).
This could have potentially informed our investigation
further on CA-AKI prophylactic provider behaviors. Seventh, we did not adjust for elective vs. urgent/emergent
procedure type, nor the presence or absence of cardiogenic shock. We did, however, adjust for the presence or
absence of CHF as well as lesion risk and number of
stents, which we felt were adequate surrogates. Eighth,
we acknowledge that contrast minimization may not

have been possible in certain cases and variability in this
may not necessarily reflect provider non-use of the
intervention.

Conclusion
In conclusion, our study demonstrated a low overall
prevalence of CA-AKI prophylaxis, and a high level of
site variation in VA catheterization laboratories for both
patients with CKD and the overall PCI population. This
variability was present with both established methods,
such as contrast minimization, and contestable methods,
such as hydration or NAC administration. There are
likely multiple factors causing this variability, including
conflicting literature, vague and contradictory guidelines,
and provider preference. Proven methods to prevent
CA-AKI, such as contrast minimization, should be standardized across the healthcare system, while further research should be pursued to establish other effective
measures to prevent CA-AKI, and prospectively evaluate
the influence of standardized CA-AKI prophylaxis protocols on patient outcomes.
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